OXE-103 program (Oxeia)

N/A

Report date: 2025/01/26 16:32:51

Base Information

Drug NameOXE-103 program (Oxeia)
Drug Alias Namehuman ghrelin (Daiichi Sankyo)synthetic ghrelin (KineMed)human ghrelin (Daiichi Suntory)synthetic human ghrelin (Oxeia Biopharmaceuticals)human ghrelin (Daiichi Asubio Pharma) +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGhrelin/growth hormone secretagogue receptor agonists
TargetsGhrelin/growth hormone secretagogue receptor
Therapy Area/IndicationsAnorexia NervosaCachexiaMuscular Atrophy +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEuropeJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAsubio Pharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOxeia Biopharmaceuticals Inc
Inactive CompaniesKinemed IncAsubio Pharma Co Ltd
Active IndicationsBrain Injuries, Traumatic
Inactive IndicationsAnorexia NervosaCachexiaMuscular Atrophy

Other Information

ATC CodeN/A
Related LinksN/A